参考文献:1.Iyer NG, Morris LGT, Tuttle RM, Shaha AR, Ganly I (2011) Rising incidence of second cancers in patients with low-risk (T1N0) thyroid cancer who receive radioactive iodine therapy. Cancer 117(19):4439–4446. doi:10.1002/cncr.26070 CrossRef PubMed PubMedCentral 2.Cancer of the thyroid—SEER stat fact sheets. http://seer.cancer.gov/statfacts/html/thyro.html . Accessed 8 Feb 2015 3.Sawka AM, Thabane L, Parlea L et al (2009) Second primary malignancy risk after radioactive iodine treatment for thyroid cancer: a systematic review and meta-analysis. Thyroid Off J Am Thyroid Assoc 19(5):451–457. doi:10.1089/thy.2008.0392 CrossRef 4.Mauritzson N, Albin M, Rylander L et al (2002) Pooled analysis of clinical and cytogenetic features in treatment-related and de novo adult acute myeloid leukemia and myelodysplastic syndromes based on a consecutive series of 761 patients analyzed 1976–1993 and on 5098 unselected cases reported in the literature 1974–2001. Leukemia 16(12):2366–2378. doi:10.1038/sj.leu.2402713 CrossRef PubMed 5.Schoch C, Kern W, Schnittger S, Hiddemann W, Haferlach T (2004) Karyotype is an independent prognostic parameter in therapy-related acute myeloid leukemia (t-AML): an analysis of 93 patients with t-AML in comparison to 1091 patients with de novo AML. Leukemia 18(1):120–125. doi:10.1038/sj.leu.2403187 CrossRef PubMed 6.Schroeder T, Kuendgen A, Kayser S et al (2012) Therapy-related myeloid neoplasms following treatment with radioiodine. Haematologica 97(2):206–212. doi:10.3324/haematol.2011.049114 CrossRef PubMed PubMedCentral 7.Bitton R, Sachmechi I, Benegalrao Y, Schneider BS (1993) Leukemia after a small dose of radioiodine for metastatic thyroid cancer. J Clin Endocrinol Metab 77(5):1423–1426. doi:10.1210/jcem.77.5.8077344 PubMed 8.Grudeva-Popova J, Yaneva M, Zisov K, Ananoshtev N (2007) Therapy-related acute promyelocytic leukemia after treatment with radioiodine for thyroid cancer: case report with literature review. J BUON Off J Balk Union Oncol 12(1):129–132 9.Gilabert M, Prebet T (2012) Acute leukemia arising after radioiodine treatment for thyroid cancer. Haematologica 97(8):e28–e29. doi:10.3324/haematol.2012.067454 CrossRef PubMed PubMedCentral 10.Lee SH, Eom KS, Lee S et al (2006) A case of acute promyelocytic leukemia after iodine-131 treatment for thyroid cancer. Korean J Hematol 41(4):302. doi:10.5045/kjh.2006.41.4.302 CrossRef 11.Roldán-Schilling V, Fernández Abellán P, Domínguez Escribano JR, Rivas González C, Mut Barberá E, Calatayud Cendra R (1998) Acute leukemias after treatment with radioiodine for thyroid cancer. Haematologica 83(8):767–768PubMed 12.Ankit J, Premalata CS, Saini KS et al (2009) Acute myeloid leukemia following radioactive iodine therapy for papillary carcinoma of the thyroid. Turk J Hematol 26:97–99 13.Trikalinos NA, Chen Q, Ning Y, Sausville EA, Baer MR (2013) Unbalanced 11;18 translocation in an acute erythroid leukemia after radioactive iodine therapy. Cancer Genet 206(6):252–255. doi:10.1016/j.cancergen.2013.06.003 CrossRef PubMed 14.Laurenti L, Salutari P, Sica S et al (1998) Acute myeloid leukemia after iodine-131 treatment for thyroid disorders. Ann Hematol 76(6):271–272CrossRef PubMed 15.Jeong JH, Ahn JY, Park SH, Park MJ, Kim KH, Hong JS (2012) A case of therapy-related acute myeloid leukemia with inv(16)(p13.1q22) after single low-dose iodine-131 treatment for thyroid cancer. Korean J Hematol 47(3):225–228. doi:10.5045/kjh.2012.47.3.225 CrossRef PubMed PubMedCentral 16.Weingertner AS, Wilt M, Atallah I, Fohrer C, Mauvieux L, Rodier J-F (2009) Myeloid sarcoma of the uterine cervix as presentation of acute myeloid leukaemia after treatment with low-dose radioiodine for thyroid cancer: a case report and review of the literature. Case Rep Oncol 2(1):1–6. doi:10.1159/000191215 CrossRef PubMed PubMedCentral 17.Richards EM, Marcus RE (1993) Acute promyelocytic leukaemia following radioiodine therapy. Clin Lab Haematol 15(1):55–58CrossRef PubMed 18.Takemoto Y, Hata T, Kamino K et al (1995) Leukemia developing after 131I treatment for thyroid cancer in a patient with Werner’s syndrome: molecular and cytogenetic studies. Intern Med 34(9):863–867. doi:10.2169/internalmedicine.34.863 CrossRef PubMed 19.Beierwaltes WH (1981) New horizons for therapeutic nuclear medicine in 1981. J Nucl Med 22(6):549–554PubMed 20.Siemsen JK (1970) Leukemia following cancericidal doses of radioiodine. J Nucl Med 11:400 21.Blom PS, Querido A, Leeksma CH (1955) Acute leukaemia following x-ray and radioiodine treatment of thyroid carcinoma. Br J Radiol 28(327):165–166CrossRef PubMed 22.Lahoud OB, Ajay D, Chandra AB. Early occurrence of therapy-related acute myeloid leukemia (t-AML) with monocytic differentiation with trisomy 8 cytogenetic abnormality after radioactive iodine (RAI) treatment for papillary thyroid cancer. Blood J. http://www.bloodjournal.org/content/124/21/5325?sso-checked=true . Accessed 26 May 2015 23.Delarue J, Tubiana M, Dutreix J (1953) Cancer of the thyroid treated with radioactive iodine; termination by acute leukemia after an important amelioration. Bull Assoc Fr Pour Létude Cancer 40(3):263–271 24.Seidlin SM, Siegal E, Yalow AA, Melamed S (1956) Acute myeloid leukemia following prolonged iodine-131 therapy for metastatic thyroid carcinoma. Science 123(3201):800–801CrossRef PubMed 25.Jelliffe AM, Jones KM (1960) Leukaemia after radioiodine therapy for thyroid cancer. Clin Radiol 11:134–135CrossRef PubMed 26.Pochin E (1969) Long-term hazards of radioiodine treatment of thyroid carcinoma. In: Hedinger C (ed) Thyroid cancer, vol 12., UICC monograph seriesSpringer, Berlin, pp 293–304 27.Lewallen CG, Godwin JT (1963) Acute myelogenous leukemia complicating radioactive iodine therapy of thyroid cancer. Report of a case. Am J Roentgenol Radium Ther Nucl Med 89:610–617PubMed 28.Brincker H, Hansen HS, Andersen AP (1973) Induction of leukaemia by 131I treatment of thyroid carcinoma. Br J Cancer 28(3):232–237CrossRef PubMed PubMedCentral 29.Uppin MS, Paul TR, Rajappa S, Gayathri K, Jacob R, Uppin SG (2007) Leukemia as a second malignancy. Indian J Pathol Microbiol 50(3):644–647PubMed 30.Döhner H, Estey EH, Amadori S et al (2010) Diagnosis and management of acute myeloid leukemia in adults: recommendations from an international expert panel, on behalf of the European LeukemiaNet. Blood 115(3):453–474. doi:10.1182/blood-2009-07-235358 CrossRef PubMed 31.Smith SM, Le Beau MM, Huo D et al (2003) Clinical-cytogenetic associations in 306 patients with therapy-related myelodysplasia and myeloid leukemia: the University of Chicago series. Blood 102(1):43–52. doi:10.1182/blood-2002-11-3343 CrossRef PubMed 32.Noaparast Z, Hosseinimehr SJ (2013) Radioprotective agents for the prevention of side effects induced by radioiodine-131 therapy. Future Oncol 9(8):1145–1159. doi:10.2217/fon.13.79 CrossRef PubMed 33.Li L, Li M, Sun C et al (2011) Altered hematopoietic cell gene expression precedes development of therapy-related myelodysplasia/acute myeloid leukemia and identifies patients at risk. Cancer Cell 20(5):591–605. doi:10.1016/j.ccr.2011.09.011 CrossRef PubMed PubMedCentral
1. Department of Medicine, Reading Health System, Sixth Avenue and Spruce Street, West Reading, PA, 19611, USA 2. Department of Hematology and Medical Oncology, Winship Cancer Institute of Emory University, 1365C Clifton Road NE, Suite 5010, Atlanta, GA, 30322, USA
刊物类别:Medicine
刊物主题:Medicine & Public Health Oncology Cancer Research Public Health Epidemiology Hematology
出版者:Springer Netherlands
ISSN:1573-7225
文摘
Background Therapy-related acute myeloid leukemia (t-AML) associated with radioiodine treatment (RAI) is emerging as an important clinical entity with the rise in incidence of thyroid cancer.